Suche
Mein Konto
NTC014: Revolutionary eye drops against bacterial conjunctivitis!
NTC Presents Positive Phase II Results for NTC014, a New Eye Drop Product for the Treatment of Bacterial Conjunctivitis.
NTC014: Revolutionary eye drops against bacterial conjunctivitis!
The American and Asian pharmaceutical world is on the verge of a revolution in the treatment of bacterial conjunctivitis. NTC, a research-focused pharmaceutical company headquartered in Italy, has published groundbreaking results from the Phase II MIRAKLE trial. This multicenter study studies the novel drug NTC014, a combination of a quinolone antibiotic and a nonsteroidal anti-inflammatory drug (NSAID) in the form of eye drops. According to NTC, the results are consistent with the idea of using fewer antibiotics, which can reduce treatment costs and the risk of antibiotic resistance. “These preliminary results confirm that NTC014 has potential as a new treatment for bacterial conjunctivitis,” explains Alessandro Colombo, Chief Scientific Officer at NTC, highlighting the drug's great potential.
In addition to the positive study results, NTC has entered into an exclusive license agreement with Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, allowing Zhaoke to commercialize NTC014 in China and several other Asian markets. This strategy aims to offer physicians an innovative and effective treatment option for moderate bacterial conjunctivitis. “We are proud to partner with Zhaoke, an innovative company,” said Riccardo Carbucicchio, CEO of NTC. “NTC014 will make a world-class treatment available to millions of patients,” he added, while emphasizing the importance of NTC014 in fighting bacterial infections.
Innovative treatment in sight
The product, which is a first-in-class oral solution, combines a powerful antibiotic with an NSAID that controls the symptoms and signs of inflammation. This innovative solution will not only increase the efficiency of treatment, but also support NTC's plans to reduce the number of medications required and the duration of treatment. Dr. Benjamin Li, CEO of Zhaoke, expressed excitement about the collaboration: “This partnership with NTC perfectly aligns with our mission to bring innovative therapies to China and Asian markets.” The development of NTC014 could therefore lead to a significant improvement in medical care in ophthalmology, as NTC also highlighted in its press release. For more information about NTC and its products, visit their website NTC Pharma.